Remdesivir

CHEMBL4065616 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

602.6 g/mol

LogP

1.9

Phase

4

An antiviral medication originally developed for hepatitis C and Ebola that has been approved for treating COVID-19 and studied for other viral infections. It works by mimicking a building block of RNA to disrupt viral replication.

Masse moléculaire

602,6000 g/mol

LogP

1,90

TPSA

204,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Pain Management Asthma Insomnia Deep Vein Thrombosis / Pulmonary Embolism Hypertension Chronic Pain HIV/AIDS Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1

InChI

InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1

Molecular Formula

C27H35N6O8P

HBD / HBA

4 / 13

Liaisons Rotatives

14

Atomes Lourds

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antiviral medication originally developed for hepatitis C and Ebola that has been approved for treating COVID-19 and studied for other viral infections. It works by mimicking a building block of RNA to disrupt viral replication.

Yes, Remdesivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4065616. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 121304016. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Remdesivir sur PillFYI

Structure

Données Clés

Formule: C27H35N6O8P
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.